- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Egetis Therapeutics AB (publ) (EGTX)
Egetis Therapeutics AB (publ) stock price live, this page displays ST EGTX stock exchange data. View the EGTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Egetis Therapeutics AB (publ) real time stock price chart below.
What Is the Egetis Therapeutics AB (publ) Stock Price Today?
The Egetis Therapeutics AB (publ) stock price today is 5.51.
What Is the Stock Symbol for Egetis Therapeutics AB (publ)?
The stock symbol for Egetis Therapeutics AB (publ) is "EGTX."
What Stock Exchange Does Egetis Therapeutics AB (publ) Trade On?
Egetis Therapeutics AB (publ) is listed and trades on the Stockholm stock exchange.
Is Egetis Therapeutics AB (publ) a Good Stock to Buy?
Determining whether Egetis Therapeutics AB (publ)—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EGTX quote. (ISIN: SE0003815604)
What Is the Egetis Therapeutics AB (publ) Stock Price Today?
The Egetis Therapeutics AB (publ) stock price today is 5.51.
What Is the Stock Symbol for Egetis Therapeutics AB (publ)?
The stock symbol for Egetis Therapeutics AB (publ) is "EGTX."
What Stock Exchange Does Egetis Therapeutics AB (publ) Trade On?
Egetis Therapeutics AB (publ) is listed and trades on the Stockholm stock exchange.
Is Egetis Therapeutics AB (publ) a Good Stock to Buy?
Determining whether Egetis Therapeutics AB (publ)—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EGTX quote. (ISIN: SE0003815604)
Stockholm
Currency in SEK
5.51
-0.17(-2.99%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.48
5.68
52 wk Range
3.03
7.07
Earnings results expected in 12 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.485.68
52 wk Range
3.037.07
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EGTX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
9.40
Upside
+70.60%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.
Egetis Therapeutics AB (publ) Earnings Call Summary for Q3/2025
- Egetis Therapeutics reported Q3 revenue of SEK 17.4M (up 85% YoY) despite a 4.49% stock decline following earnings call
- Company secured Breakthrough Therapy Designation for Triac and reported statistically significant results from ReTRIEVE study
- Operating losses slightly improved to -SEK 219.6M, with cash position of SEK 145.7M bolstered by SEK 172M from post-period rights issue
- Management plans rolling NDA submission for MCT8 deficiency in December 2025, with potential U.S. launch targeted for H2 2026
- Continued operating losses and potential regulatory delays remain key challenges despite positive clinical advancements
Last Updated: 2025-11-25, 04:46 a/m
Read Full TranscriptCompare EGTX to Peers and Sector
Metrics to compare | EGTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEGTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.6x | 216.3x | −0.5x | |
PEG Ratio | −0.39 | 1.74 | 0.00 | |
Price/Book | 6.6x | 3.4x | 2.6x | |
Price / LTM Sales | 36.0x | 8.8x | 3.2x | |
Upside (Analyst Target) | 89.3% | 95.8% | 45.6% | |
Fair Value Upside | Unlock | −1.8% | 5.3% | Unlock |
Analyst Ratings
2 Buy
0 Hold
1 Sell
Ratings:
3 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 9.40
(+70.60% Upside)
Earnings
Latest Release
Feb 26, 2026
EPS / Forecast
-0.29 / -0.23
Revenue / Forecast
17.9M / 21.47M
People Also Watch
FAQ
What Is the Egetis Therapeutics AB (EGTX) Stock Price Today?
The Egetis Therapeutics AB stock price today is 5.51 SEK.
What Stock Exchange Does Egetis Therapeutics AB Trade On?
Egetis Therapeutics AB is listed and trades on the Stockholm Stock Exchange.
What Is the Stock Symbol for Egetis Therapeutics AB?
The stock symbol for Egetis Therapeutics AB is "EGTX."
What Is the Egetis Therapeutics AB Market Cap?
As of today, Egetis Therapeutics AB market cap is 2.17B SEK.
What Is Egetis Therapeutics AB's Earnings Per Share (TTM)?
The Egetis Therapeutics AB EPS (TTM) is -0.93.
When Is the Next Egetis Therapeutics AB Earnings Date?
Egetis Therapeutics AB will release its next earnings report on Apr 29, 2026.
From a Technical Analysis Perspective, Is EGTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Egetis Therapeutics AB Stock Split?
Egetis Therapeutics AB has split 4 times.
How Many Employees Does Egetis Therapeutics AB Have?
Egetis Therapeutics AB has 42 employees.
What is the current trading status of Egetis Therapeutics AB (EGTX)?
As of Apr 17, 2026, Egetis Therapeutics AB (EGTX) is trading at a price of 5.51 SEK, with a previous close of 5.68 SEK. The stock has fluctuated within a day range of 5.48 SEK to 5.68 SEK, while its 52-week range spans from 3.03 SEK to 7.07 SEK.
What Is Egetis Therapeutics AB (EGTX) Price Target According to Analysts?
The average 12-month price target for Egetis Therapeutics AB is 9.40 SEK, with a high estimate of 14.5 SEK and a low estimate of 1.6 SEK. 2 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +70.60% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.